VivoSeq
Musculoskeletal

Postmenopausal Osteoporosis

42

Pipeline Programs↗

7

Active Trials↗

25

Companies Involved↗

Postmenopausal Osteoporosis is a moderately active landscape with 42 programs across 25 companies. The most active players are Shenzhen Salubris Pharmaceuticals Co., Ltd., Tarsa Therapeutics, Inc., Merck & Co.. 15 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

15/100

Mech. Concentration

29/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shenzhen Salubris Pharmaceuticals Co., Ltd.

2 programs

Phase 2T

Tarsa Therapeutics, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2L

Ligand Pharmaceuticals

1 program

Phase 2Takeda logo

Takeda

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 3

Pipeline

Programs by Phase

Preclinical7

Denosumab

Amgen

Romosozumab

Amgen

Alendronate Sodium

Mylan Pharmaceuticals Inc

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Alendronate

Organon and Co

Phase 12

Calcitriol

Alnylam Pharmaceuticals

SHR-1222

Jiangsu HengRui Medicine Co., Ltd.

Phase 26

Odanacatib

Merck & Co.

ALX1-11

Takeda

Sodium Pentaborate

Tabriz University of Medical Sciences

Teriparatide Acetate(teribone™)

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Rhpth（1-34） 28.2μg

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Phase 312

Calcium Carbonate

Otsuka

Calcium

Eli Lilly

Risedronate

Vitae Pharmaceuticals Inc., an Allergan affiliate

Alfacalcidol

Roche

Prolia

Qilu Pharmaceutical Co., Ltd.

Approved15

Estradiol

Novo Nordisk

Raloxifene

Eli Lilly

Zoledronic Acid

Pfizer

Midazolam

Conrado Roberto Hoffmann Filho

Ergocalciferol

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

92%

Small molecule

46 of 50 classified programs — the dominant modality here.

8%ALL OTHERSMonoclonal antibody36%Peptide12%

Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 100% of 54 pipeline programs.

Analysis

Trial Status

52

clinical trials

Completed39 · 75%
Unknown status6 · 12%
Recruiting3 · 6%
Not yet recruiting2 · 4%
Active, not recruiting2 · 4%

Clinical Trials

Trial Activity

52 trials

StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
Recruiting·UUniversity Hospital, Toulouse·Phase 4·NCT06767150·200 enrolled
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
Recruiting·KKhyber Medical University Peshawar·N/A·NCT07242612·40 enrolled
Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis
Recruiting·NNational Taiwan University Hospital·Phase 4·NCT07283887·90 enrolled
Anabolic Therapy in Postmenopausal Osteoporosis
Active, not recruiting·MMassachusetts General Hospital·Phase 4·NCT05010590·50 enrolled
Randomized Control Trial of Dietary Supplementation With Dried Plums on Bone Density, Geometry and Estimated Bone Strength in Postmenopausal Women
Active, not recruiting·PPenn State University·Preclinical·NCT02822378·322 enrolled
Efficacy of OsteoBor in Postmenopausal Osteoporosis
Not yet recruiting·TTabriz University of Medical Sciences·Phase 2·NCT06809816·30 enrolled
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
Not yet recruiting·MMarmara University·Phase 4·NCT06720350·60 enrolled
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
Completed·Eli Lilly logoEli Lilly·Phase 4·NCT00191425·810 enrolled
PROPOSE Quality - PReOtact in Postmenopausal OStEoporosis - Quality of Life Study (FP-004-DE)
Completed·NNycomed·N/A·NCT00515593·110 enrolled
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
Completed·—·Phase 3·NCT00092014·1,053 enrolled
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Completed·Takeda logoTakeda·Phase 2·NCT00172107·217 enrolled
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
Completed·UUniversity of Valencia·Phase 4·NCT01544894·80 enrolled
Julina Post-marketing Surveillance for Postmenopausal Osteoporosis in Japan
Completed·Bayer logoBayer·N/A·NCT01397955·148 enrolled
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Completed·Amgen logoAmgen·Phase 3·NCT00089791·7,808 enrolled
A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients
Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT04435158·107 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)